메뉴 건너뛰기




Volumn 13, Issue 3, 2014, Pages 295-305

Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: Efficacy and safety

Author keywords

Anti endothelin 1; Phosphodiesterase type 5 inhibitors; Prostanoids; Systemic sclerosis related pulmonary arterial hypertension; TNF inhibitors

Indexed keywords

AMBRISENTAN; AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; BERAPROST; BOSENTAN; ILOPROST; MACITENTAN; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; TREPROSTINIL;

EID: 84896735712     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.872238     Document Type: Review
Times cited : (20)

References (94)
  • 1
    • 0036733723 scopus 로고    scopus 로고
    • Increased prevalence of scleroderma in southwestern Ontario: A cluster analysis
    • Thompson AE, Pope JE. Increased prevalence of scleroderma in southwestern Ontario: A cluster analysis. J Rheumatol 2002;29:1867-73
    • (2002) J Rheumatol , vol.29 , pp. 1867-1873
    • Thompson, A.E.1    Pope, J.E.2
  • 2
    • 33847621190 scopus 로고    scopus 로고
    • Outcome measurements in scleroderma: Results from a Delphi exercise
    • Gazi H, Pope JE, Clements P, et al. Outcome measurements in scleroderma: Results from a Delphi exercise. J Rheumatol 2007;34:501-9
    • (2007) J Rheumatol , vol.34 , pp. 501-509
    • Gazi, H.1    Pope, J.E.2    Clements, P.3
  • 3
    • 82555191287 scopus 로고    scopus 로고
    • Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening
    • Denton CP, Hachulla E. Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. Eur Respir Rev 2011;20(122):270-64
    • (2011) Eur Respir Rev , vol.20 , Issue.122 , pp. 270-264
    • Denton, C.P.1    Hachulla, E.2
  • 4
    • 34347266509 scopus 로고    scopus 로고
    • Changes in causes of death in systemic sclerosis 1972-2002
    • Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann rheum Dis 2007;66(7):940-4
    • (2007) Ann Rheum Dis , vol.66 , Issue.7 , pp. 940-944
    • Steen, V.D.1    Medsger, T.A.2
  • 5
    • 19944427793 scopus 로고    scopus 로고
    • Mortality in systemic sclerosis: An international meta-analysis of individual patient data
    • Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: An international meta-analysis of individual patient data. Am J Med 2005;118(1):2-10
    • (2005) Am J Med , vol.118 , Issue.1 , pp. 2-10
    • Ioannidis, J.P.1    Vlachoyiannopoulos, P.G.2    Haidich, A.B.3
  • 6
    • 0038799768 scopus 로고    scopus 로고
    • Pulmonary hypertension in systemic sclerosis
    • vii
    • Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003;29(2):335-49; vii
    • (2003) Rheum Dis Clin North Am , vol.29 , Issue.2 , pp. 335-349
    • Denton, C.P.1    Black, C.M.2
  • 7
    • 29144536869 scopus 로고    scopus 로고
    • Early detection of pulmonary arterial hypertension in systemic sclerosis a French nationwide prospective multicenter study
    • Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheum 2005;52(12):3792-800
    • (2005) Arthritis Rheum , vol.52 , Issue.12 , pp. 3792-3800
    • Hachulla, E.1    Gressin, V.2    Guillevin, L.3
  • 8
    • 22244434954 scopus 로고    scopus 로고
    • The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study)
    • Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52(7):2125-32
    • (2005) Arthritis Rheum , vol.52 , Issue.7 , pp. 2125-2132
    • Wigley, F.M.1    Lima, J.A.2    Mayes, M.3
  • 9
    • 2942541475 scopus 로고    scopus 로고
    • Cellular and molecular pathobiology of pulmonary arterial hypertension
    • Suppl I
    • Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):13S-24S
    • (2004) J Am Coll Cardiol , vol.43 , Issue.12
    • Humbert, M.1    Morrell, N.W.2    Archer, S.L.3
  • 10
    • 84866539030 scopus 로고    scopus 로고
    • Endothelial dysfunction in rheumatic autoimmune diseases
    • Murdaca G, Colombo BM, Cagnati P, et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012;224(2):309-17
    • (2012) Atherosclerosis , vol.224 , Issue.2 , pp. 309-317
    • Murdaca, G.1    Colombo, B.M.2    Cagnati, P.3
  • 11
    • 84878959825 scopus 로고    scopus 로고
    • Free radicals and endothelial dysfunction: Potential positive effects of TNF-alpha inhibitors
    • Murdaca G, Spanò F, Cagnati P, Puppo F. Free radicals and endothelial dysfunction: Potential positive effects of TNF-alpha inhibitors. Redox Rep 2013;18(3):95-9
    • (2013) Redox Rep , vol.18 , Issue.3 , pp. 95-99
    • Murdaca, G.1    Spanò, F.2    Cagnati, P.3    Puppo, F.4
  • 12
    • 0348110529 scopus 로고    scopus 로고
    • Endothelial function, inflammation, and prognosis in cardiovascular disease
    • Gonzalez MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003;115(Suppl 8A):99S-106S
    • (2003) Am J Med , vol.115 , Issue.SUPPL.
    • Gonzalez, M.A.1    Selwyn, A.P.2
  • 14
    • 50949084102 scopus 로고    scopus 로고
    • Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus
    • Ciprandi G, Murdaca G, Colombo BM, et al. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol 2008;69(8):510-12
    • (2008) Hum Immunol , vol.69 , Issue.8 , pp. 510-512
    • Ciprandi, G.1    Murdaca, G.2    Colombo, B.M.3
  • 15
    • 45149117511 scopus 로고    scopus 로고
    • Serum vascular endothelial growth factor and sublingual immunotherapy
    • Ciprandi G, Colombo BM, Murdaca G, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy 2008;63(7):945-6
    • (2008) Allergy , vol.63 , Issue.7 , pp. 945-946
    • Ciprandi, G.1    Colombo, B.M.2    Murdaca, G.3    De Amici, M.4
  • 16
    • 0032777126 scopus 로고    scopus 로고
    • Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cellspecific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth
    • Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cellspecific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999;155:411-19
    • (1999) Am J Pathol , vol.155 , pp. 411-419
    • Cool, C.D.1    Stewart, J.S.2    Werahera, P.3
  • 17
    • 84866618858 scopus 로고    scopus 로고
    • Immune and inflammatory mechanisms in pulmonary arterial hypertension
    • El Chami H, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis 2012;55(2):218-28
    • (2012) Prog Cardiovasc Dis , vol.55 , Issue.2 , pp. 218-228
    • El Chami, H.1    Hassoun, P.M.2
  • 18
    • 0029062419 scopus 로고
    • Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension
    • Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:1628-31
    • (1995) Am J Respir Crit Care Med , vol.151 , pp. 1628-1631
    • Humbert, M.1    Monti, G.2    Brenot, F.3
  • 19
    • 7044224579 scopus 로고    scopus 로고
    • Infliximab improves endothelial dysfunction in systemic vasculitis: A model of vascular inflammation
    • Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: A model of vascular inflammation. Circulation 2004;109(14):1718-23
    • (2004) Circulation , vol.109 , Issue.14 , pp. 1718-1723
    • Booth, A.D.1    Jayne, D.R.2    Kharbanda, R.K.3
  • 21
    • 80052459025 scopus 로고    scopus 로고
    • Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNF-alpha contributes to the pathogenesis of pulmonary arterial hypertension
    • Sutendra G, Dromparis P, Bonnet S, et al. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNF-alpha contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl) 2011;89(8):771-83
    • (2011) J Mol Med (Berl , vol.89 , Issue.8 , pp. 771-783
    • Sutendra, G.1    Dromparis, P.2    Bonnet, S.3
  • 22
    • 84873721826 scopus 로고    scopus 로고
    • Interleukin-17a+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement
    • Truchetet ME, Brembilla NC, Montanari E, et al. Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. Arthritis Rheum 2013;65(5):1347-56
    • (2013) Arthritis Rheum , vol.65 , Issue.5 , pp. 1347-1356
    • Truchetet, M.E.1    Brembilla, N.C.2    Montanari, E.3
  • 23
    • 81955160918 scopus 로고    scopus 로고
    • The role of th17 lymphocytes in the autoimmune and chronic inflammatory diseases
    • Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med 2011;6(6):487-95
    • (2011) Intern Emerg Med , vol.6 , Issue.6 , pp. 487-495
    • Murdaca, G.1    Colombo, B.M.2    Puppo, F.3
  • 24
    • 61349192714 scopus 로고    scopus 로고
    • Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: Role of vascular endothelial growth factor (VEGATS Study)
    • Colombo BM, Cacciapaglia F, Puntoni M, et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: Role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev 2009;8(4):309-15
    • (2009) Autoimmun Rev , vol.8 , Issue.4 , pp. 309-315
    • Colombo, B.M.1    Cacciapaglia, F.2    Puntoni, M.3
  • 25
    • 34948901886 scopus 로고    scopus 로고
    • Intima-media thickness: A marker of accelerated atherosclerosis in women with systemic lupus erythematosus
    • Colombo BM, Murdaca G, Caiti M, et al. Intima-media thickness: A marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann NY Acad Sci 2007;1108:121-6
    • (2007) Ann NY Acad Sci , vol.1108 , pp. 121-126
    • Colombo, B.M.1    Murdaca, G.2    Caiti, M.3
  • 26
    • 0037331116 scopus 로고    scopus 로고
    • Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis
    • Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123(2):344-50
    • (2003) Chest , vol.123 , Issue.2 , pp. 344-350
    • Kawut, S.M.1    Taichman, D.B.2    Archer-Chicko, C.L.3
  • 27
    • 77954758530 scopus 로고    scopus 로고
    • Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era
    • Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63
    • (2010) Circulation , Issue.122 , pp. 156-163
    • Humbert, M.1    Sitbon, O.2    Chaouat, A.3
  • 28
    • 77951961897 scopus 로고    scopus 로고
    • Survival in pulmonary arterial hypertension: A reappraisal of the NIH risk stratification equation
    • Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: A reappraisal of the NIH risk stratification equation. Eur Respir J 2010;35:1079-87
    • (2010) Eur Respir J , Issue.35 , pp. 1079-1087
    • Thenappan, T.1    Shah, S.J.2    Rich, S.3
  • 29
    • 77957286169 scopus 로고    scopus 로고
    • Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database
    • Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15
    • (2010) Ann Rheum Dis , vol.69 , pp. 1809-1815
    • Tyndall, A.J.1    Bannert, B.2    Vonk, M.3
  • 30
    • 77955953602 scopus 로고    scopus 로고
    • Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
    • Humbert M, Sitbon O, Yai?ci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:549-55
    • (2010) Eur Respir J , Issue.36 , pp. 549-555
    • Humbert, M.1    Sitbon, O.2    Yaici, A.3
  • 31
    • 58449122578 scopus 로고    scopus 로고
    • Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era
    • Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-7
    • (2009) Am J Respir Crit Care Med , vol.179 , pp. 151-157
    • Condliffe, R.1    Kiely, D.G.2    Peacock, A.J.3
  • 32
    • 74549213864 scopus 로고    scopus 로고
    • Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension
    • Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010;121:20-5
    • (2010) Circulation , Issue.121 , pp. 20-25
    • Dimopoulos, K.1    Inuzuka, R.2    Goletto, S.3
  • 33
    • 0038441800 scopus 로고    scopus 로고
    • Bosentan for the treatment of pulmonary arterial hypertension
    • Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother 2003;37(7-8):1055-62
    • (2003) Ann Pharmacother , vol.37 , Issue.7-8 , pp. 1055-1062
    • Kenyon, K.W.1    Nappi, J.M.2
  • 34
    • 66149100618 scopus 로고    scopus 로고
    • EUSTAR Co-Authors EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR)
    • Kowal-Bielecka O, Landewé R, Avouac J, et al. EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68(5):620-8
    • (2009) Ann Rheum Dis , vol.68 , Issue.5 , pp. 620-628
    • Kowal-Bielecka, O.1    Landewé, R.2    Avouac, J.3
  • 35
    • 0037149718 scopus 로고    scopus 로고
    • Bosentan therapy for pulmonary arterial hypertension
    • Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896-903
    • (2002) N Engl J Med , vol.346 , Issue.12 , pp. 896-903
    • Rubin, L.J.1    Badesch, D.B.2    Barst, R.J.3
  • 36
    • 0020410785 scopus 로고
    • Psychophysical bases of perceived exertion
    • Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14(5):377-81
    • (1982) Med Sci Sports Exerc , vol.14 , Issue.5 , pp. 377-381
    • Borg, G.A.1
  • 37
    • 4544383466 scopus 로고    scopus 로고
    • Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
    • Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24(3):353-9
    • (2004) Eur Respir J , vol.24 , Issue.3 , pp. 353-359
    • Humbert, M.1    Barst, R.J.2    Robbins, I.M.3
  • 38
    • 20044372707 scopus 로고    scopus 로고
    • Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension
    • Sasayama S, Kunieda T, Tomoike H, et al. Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. Circ J 2005;69(2):131-7
    • (2005) Circ J , vol.69 , Issue.2 , pp. 131-137
    • Sasayama, S.1    Kunieda, T.2    Tomoike, H.3
  • 39
    • 57649188679 scopus 로고    scopus 로고
    • N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment
    • Dimitroulas T, Giannakoulas G, Karvounis H, et al. N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment. Rheumatol Int 2009;29(3):347-8
    • (2009) Rheumatol Int , vol.29 , Issue.3 , pp. 347-348
    • Dimitroulas, T.1    Giannakoulas, G.2    Karvounis, H.3
  • 40
    • 33746206340 scopus 로고    scopus 로고
    • Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebocontrolled study
    • Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebocontrolled study. Circulation 2006;114:48-54
    • (2006) Circulation , vol.114 , pp. 48-54
    • Galiè, N.1    Beghetti, M.2    Gatzoulis, M.A.3
  • 41
    • 58249107821 scopus 로고    scopus 로고
    • Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities
    • McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009;135:122-9
    • (2009) Chest , vol.135 , pp. 122-129
    • McGoon, M.D.1    Frost, A.E.2    Oudiz, R.J.3
  • 42
    • 46449124591 scopus 로고    scopus 로고
    • Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2
    • Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double- Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group
    • Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double- Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010-19
    • (2008) Circulation , vol.117 , Issue.23 , pp. 3010-3019
    • Galiè, N.1    Olschewski, H.2    Oudiz, R.J.3
  • 43
    • 70350708667 scopus 로고    scopus 로고
    • Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension
    • Oudiz RJ, Galiè N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(21):1971-81
    • (2009) J Am Coll Cardiol , vol.54 , Issue.21 , pp. 1971-1981
    • Oudiz, R.J.1    Galiè, N.2    Olschewski, H.3
  • 44
    • 84858279164 scopus 로고    scopus 로고
    • ARIES-3: Ambrisentan therapy in a diverse population of patients with pulmonary hypertension
    • Badesch DB, Feldman J, Keogh A, et al. ARIES-3: Ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012;30(2):93-9
    • (2012) Cardiovasc Ther , vol.30 , Issue.2 , pp. 93-99
    • Badesch, D.B.1    Feldman, J.2    Keogh, A.3
  • 45
    • 84886518672 scopus 로고    scopus 로고
    • Ambrisentan for the treatment of pulmonary arterial hypertension: Improving outcomes
    • Elshaboury SM, Anderson Jr. Ambrisentan for the treatment of pulmonary arterial hypertension: Improving outcomes. Patient Prefer Adherence 2013;7:401-9
    • (2013) Patient Prefer Adherence , Issue.7 , pp. 401-409
    • Elshaboury, S.M.1    Anderson, J.R.2
  • 46
    • 84867754027 scopus 로고    scopus 로고
    • Safety and efficacy evaluation of ambrisentan in pulmonary hypertension
    • Vizza CD, Fedele F, Pezzuto B, Rubin LJ. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. Expert Opin Drug Saf 2012;11(6):1003-11
    • (2012) Expert Opin Drug Saf , vol.11 , Issue.6 , pp. 1003-1011
    • Vizza, C.D.1    Fedele, F.2    Pezzuto, B.3    Rubin, L.J.4
  • 47
    • 84881617288 scopus 로고    scopus 로고
    • Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials)
    • Maron BA, Waxman AB, Opotowsky AR, et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol 2013;112(5):720-5
    • (2013) Am J Cardiol , vol.112 , Issue.5 , pp. 720-725
    • Maron, B.A.1    Waxman, A.B.2    Opotowsky, A.R.3
  • 48
    • 57349133022 scopus 로고    scopus 로고
    • Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist
    • Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327(3):736-45
    • (2008) J Pharmacol Exp Ther , vol.327 , Issue.3 , pp. 736-745
    • Iglarz, M.1    Binkert, C.2    Morrison, K.3
  • 49
    • 84867562420 scopus 로고    scopus 로고
    • Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells
    • Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 2012;7(10):e47662
    • (2012) PLoS One , vol.7 , Issue.10
    • Gatfield, J.1    Mueller Grandjean, C.2    Sasse, T.3
  • 50
    • 84883108940 scopus 로고    scopus 로고
    • Macitentan and morbidity and mortality in pulmonary arterial hypertension
    • Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369(9):809-18
    • (2013) N Engl J Med , vol.369 , Issue.9 , pp. 809-818
    • Pulido, T.1    Adzerikho, I.2    Channick, R.N.3
  • 51
    • 10744230817 scopus 로고    scopus 로고
    • Sitaxsentan therapy for pulmonary arterial hypertension
    • Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169(4):441-7
    • (2004) Am J Respir Crit Care Med , vol.169 , Issue.4 , pp. 441-447
    • Barst, R.J.1    Langleben, D.2    Frost, A.3
  • 52
    • 70349091119 scopus 로고    scopus 로고
    • Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension
    • Lavelle A, Sugrue R, Lawler G, et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J 2009;34(3):770-1
    • (2009) Eur Respir J , vol.34 , Issue.3 , pp. 770-771
    • Lavelle, A.1    Sugrue, R.2    Lawler, G.3
  • 53
    • 33847410021 scopus 로고    scopus 로고
    • The nitric oxide/cGMP signaling pathway in pulmonary hypertension
    • Klinger Jr. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 2007;28(1):143-67
    • (2007) Clin Chest Med , vol.28 , Issue.1 , pp. 143-167
    • Klinger, J.R.1
  • 54
    • 26444534291 scopus 로고    scopus 로고
    • Sildenafil citrate therapy for pulmonary arterial hypertension
    • Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353(20):2148-57
    • (2005) N Engl J Med , vol.353 , Issue.20 , pp. 2148-2157
    • Galiè, N.1    Ghofrani, H.A.2    Torbicki, A.3
  • 55
    • 80052088060 scopus 로고    scopus 로고
    • Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: The super-2 study
    • Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: The SUPER-2 study. Chest 2011;140(5):1274-83
    • (2011) Chest , vol.140 , Issue.5 , pp. 1274-1283
    • Rubin, L.J.1    Badesch, D.B.2    Fleming, T.R.3
  • 56
    • 67649523052 scopus 로고    scopus 로고
    • Tadalafil therapy for pulmonary arterial hypertension
    • Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119(22):2894-903
    • (2009) Circulation , vol.119 , Issue.22 , pp. 2894-2903
    • Galiè, N.1    Brundage, B.H.2    Ghofrani, H.A.3
  • 57
    • 84865128907 scopus 로고    scopus 로고
    • Tadalafil for the treatment of pulmonary arterial hypertension: A double-blind 52- week uncontrolled extension study
    • Oudiz RJ, Brundage BH, Galiè N, et al. Tadalafil for the treatment of pulmonary arterial hypertension: A double-blind 52- week uncontrolled extension study. J Am Coll Cardiol 2012;60(8):768-74
    • (2012) J Am Coll Cardiol , vol.60 , Issue.8 , pp. 768-774
    • Oudiz, R.J.1    Brundage, B.H.2    Galiè, N.3
  • 58
    • 84883816682 scopus 로고    scopus 로고
    • Safety tolerability and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension
    • Shapiro S, Traiger G, Hill W, et al. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension. Cardiovasc Ther 2013;31(5):274-9
    • (2013) Cardiovasc Ther , vol.31 , Issue.5 , pp. 274-279
    • Shapiro, S.1    Traiger, G.2    Hill, W.3
  • 59
    • 37749007190 scopus 로고    scopus 로고
    • Oral tadalafil in pulmonary artery hypertension: A prospective study
    • Aggarwal P, Patial RK, Negi PC, Marwaha R. Oral tadalafil in pulmonary artery hypertension: A prospective study. Indian Heart J 2007;59(4):329-35
    • (2007) Indian Heart J , vol.59 , Issue.4 , pp. 329-335
    • Aggarwal, P.1    Patial, R.K.2    Negi, P.C.3    Marwaha, R.4
  • 60
    • 84863980719 scopus 로고    scopus 로고
    • Initial experience with tadalafil in pediatric pulmonary arterial hypertension
    • Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 2012;33(5):683-8
    • (2012) Pediatr Cardiol , vol.33 , Issue.5 , pp. 683-688
    • Takatsuki, S.1    Calderbank, M.2    Ivy, D.D.3
  • 61
    • 80054752045 scopus 로고    scopus 로고
    • Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension
    • Maki H, Yao A, Inaba T, et al. Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension. Int Heart J 2011;52(5):323-6
    • (2011) Int Heart J , vol.52 , Issue.5 , pp. 323-326
    • Maki, H.1    Yao, A.2    Inaba, T.3
  • 62
    • 84862776722 scopus 로고    scopus 로고
    • Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries
    • Liang F, Yang S, Yao L, et al. Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries. Hypertension 2012;59(3):705-11
    • (2012) Hypertension , vol.59 , Issue.3 , pp. 705-711
    • Liang, F.1    Yang, S.2    Yao, L.3
  • 64
    • 0036682273 scopus 로고    scopus 로고
    • Inhaled iloprost for severe pulmonary hypertension
    • Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322-9
    • (2002) N Engl J Med , vol.347 , Issue.5 , pp. 322-329
    • Olschewski, H.1    Simonneau, G.2    Galiè, N.3
  • 65
    • 21544449424 scopus 로고    scopus 로고
    • Clinical efficacy and survival with firstline inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension
    • Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with firstline inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005;26(18):1895-902
    • (2005) Eur Heart J , vol.26 , Issue.18 , pp. 1895-1902
    • Opitz, C.F.1    Wensel, R.2    Winkler, J.3
  • 66
    • 84882259677 scopus 로고    scopus 로고
    • Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation
    • Lopez-Meseguer M, Berastegui C, Monforte V, et al. Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation. Transplant Proc 2013;45(6):2347-50
    • (2013) Transplant Proc , vol.45 , Issue.6 , pp. 2347-2350
    • Lopez-Meseguer, M.1    Berastegui, C.2    Monforte, V.3
  • 67
    • 0038037766 scopus 로고    scopus 로고
    • Beraprost therapy for pulmonary arterial hypertension
    • Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41(12):2119-25
    • (2003) J Am Coll Cardiol , vol.41 , Issue.12 , pp. 2119-2125
    • Barst, R.J.1    McGoon, M.2    McLaughlin, V.3
  • 68
    • 0025356811 scopus 로고
    • Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol) Results of a randomized trial
    • Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112(7):485-91
    • (1990) Ann Intern Med , vol.112 , Issue.7 , pp. 485-491
    • Rubin, L.J.1    Mendoza, J.2    Hood, M.3
  • 69
    • 0028597038 scopus 로고
    • Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
    • Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121(6):409-15
    • (1994) Ann Intern Med , vol.121 , Issue.6 , pp. 409-415
    • Barst, R.J.1    Rubin, L.J.2    McGoon, M.D.3
  • 70
    • 0030031888 scopus 로고    scopus 로고
    • A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
    • Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334(5):296-301
    • (1996) N Engl J Med , vol.334 , Issue.5 , pp. 296-301
    • Barst, R.J.1    Rubin, L.J.2    Long, W.A.3
  • 71
    • 0037086133 scopus 로고    scopus 로고
    • Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial
    • Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800-4
    • (2002) Am J Respir Crit Care Med , vol.165 , Issue.6 , pp. 800-804
    • Simonneau, G.1    Barst, R.J.2    Galie, N.3
  • 72
    • 77952301237 scopus 로고    scopus 로고
    • Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial
    • McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J Am Coll Cardiol 2010;55(18):1915-22
    • (2010) J Am Coll Cardiol , vol.18 , Issue.55 , pp. 1915-1922
    • McLaughlin, V.V.1    Benza, R.L.2    Rubin, L.J.3
  • 73
    • 12244251412 scopus 로고    scopus 로고
    • Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension
    • McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41(2):293-9
    • (2003) J Cardiovasc Pharmacol , vol.41 , Issue.2 , pp. 293-299
    • McLaughlin, V.V.1    Gaine, S.P.2    Barst, R.J.3
  • 74
    • 84873566367 scopus 로고    scopus 로고
    • Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: A randomized controlled trial
    • Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: A randomized, controlled trial. Circulation 2013;127(5):624-33
    • (2013) Circulation , vol.127 , Issue.5 , pp. 624-633
    • Jing, Z.C.1    Parikh, K.2    Pulido, T.3
  • 75
    • 84874948946 scopus 로고    scopus 로고
    • Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized impres study
    • Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study. Circulation 2013;127(10):1128-38
    • (2013) Circulation , vol.127 , Issue.10 , pp. 1128-1138
    • Hoeper, M.M.1    Barst, R.J.2    Bourge, R.C.3
  • 76
    • 84555190230 scopus 로고    scopus 로고
    • Update upon efficacy and safety of tnf-alpha inhibitors
    • Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-alpha inhibitors. Expert Opin Drug Saf 2012;11(1):1-5
    • (2012) Expert Opin Drug Saf , vol.11 , Issue.1 , pp. 1-5
    • Murdaca, G.1    Colombo, B.M.2    Cagnati, P.3
  • 77
    • 80855130786 scopus 로고    scopus 로고
    • Emerging biological drugs: A new therapeutic approach for systemic lupus erythematosus an update upon efficacy and adverse events
    • Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 2011;11(1):56-60
    • (2011) Autoimmun Rev , vol.11 , Issue.1 , pp. 56-60
    • Murdaca, G.1    Colombo, B.M.2    Puppo, F.3
  • 78
    • 80052748895 scopus 로고    scopus 로고
    • Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications
    • Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications. Drugs Today (Barc) 2011;47(4):277-88
    • (2011) Drugs Today (Barc , vol.47 , Issue.4 , pp. 277-288
    • Murdaca, G.1    Colombo, B.M.2    Puppo, F.3
  • 79
    • 70350551948 scopus 로고    scopus 로고
    • Anti-TNF-alpha inhibitors: A new therapeutic approach for inflammatory immune-mediated diseases: An update upon efficacy and adverse events
    • Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: A new therapeutic approach for inflammatory immune-mediated diseases: An update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009;22(3):557-65
    • (2009) Int J Immunopathol Pharmacol , vol.22 , Issue.3 , pp. 557-565
    • Murdaca, G.1    Colombo, B.M.2    Puppo, F.3
  • 80
    • 79952116693 scopus 로고    scopus 로고
    • Anti-tumor necrosis factor-alpha treatment with infliximab for disseminated granuloma annulare
    • Murdaca G, Colombo BM, Barabino G, et al. Anti-tumor necrosis factor-alpha treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol 2010;11(6):437-9
    • (2010) Am J Clin Dermatol , vol.11 , Issue.6 , pp. 437-439
    • Murdaca, G.1    Colombo, B.M.2    Barabino, G.3
  • 81
    • 26244456344 scopus 로고    scopus 로고
    • Emerging biologic drugs for the treatment of rheumatoid arthritis
    • Puppo F, Murdaca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 2005;4(8):537-41
    • (2005) Autoimmun Rev , vol.4 , Issue.8 , pp. 537-541
    • Puppo, F.1    Murdaca, G.2    Ghio, M.3    Indiveri, F.4
  • 82
    • 84886626779 scopus 로고    scopus 로고
    • Use of leflunomide plus tnf-alpha inhibitors in rheumatoid arthritis
    • Murdaca G, Spanò F, Puppo F. Use of leflunomide plus TNF-alpha inhibitors in rheumatoid arthritis. Expert Opin Drug Saf 2013;12(6):801-4
    • (2013) Expert Opin Drug Saf , vol.12 , Issue.6 , pp. 801-804
    • Murdaca, G.1    Spanò, F.2    Puppo, F.3
  • 83
    • 84874178736 scopus 로고    scopus 로고
    • Selective tnf-alpha inhibitor-induced injection site reactions
    • Murdaca G, Spanò F, Puppo F. Selective TNF-alpha inhibitor-induced injection site reactions. Expert Opin Drug Saf 2013;12(2):187-93
    • (2013) Expert Opin Drug Saf , vol.12 , Issue.2 , pp. 187-193
    • Murdaca, G.1    Spanò, F.2    Puppo, F.3
  • 84
    • 84862234099 scopus 로고    scopus 로고
    • Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment
    • Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res 2012;32(6):277-9
    • (2012) J Interferon Cytokine Res , vol.32 , Issue.6 , pp. 277-279
    • Murdaca, G.1    Colombo, B.M.2    Contini, P.3    Puppo, F.4
  • 85
    • 84867368217 scopus 로고    scopus 로고
    • Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis
    • Omair MA, Phumethum V, Johnson SR. Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis. Clin Exp Rheumatol 2012;30(2 Suppl 71):S55-9
    • (2012) Clin Exp Rheumatol , vol.30 , Issue.2 SUPPL.
    • Omair, M.A.1    Phumethum, V.2    Johnson, S.R.3
  • 86
    • 21744459538 scopus 로고    scopus 로고
    • Chronic tumor necrosis factor-alpha inhibition enhances NO modulation of vascular function in estrogen-deficient rats
    • Arenas IA, Armstrong SJ, Xu Y, Davidge ST. Chronic tumor necrosis factor-alpha inhibition enhances NO modulation of vascular function in estrogen-deficient rats. Hypertension 2005;46(1):76-81
    • (2005) Hypertension , vol.46 , Issue.1 , pp. 76-81
    • Arenas, I.A.1    Armstrong, S.J.2    Xu, Y.3    Davidge, S.T.4
  • 87
    • 84864080031 scopus 로고    scopus 로고
    • The effect of tumor necrosis factora antagonists on arterial stiffness in rheumatoid arthritis: A literature review
    • Dulai R, Perry M, Twycross-Lewis R, et al. The effect of tumor necrosis factora antagonists on arterial stiffness in rheumatoid arthritis: A literature review. Semin Arthritis Rheum 2012;42(1):1-8
    • (2012) Semin Arthritis Rheum , vol.42 , Issue.1 , pp. 1-8
    • Dulai, R.1    Perry, M.2    Twycross-Lewis, R.3
  • 88
    • 75049085546 scopus 로고    scopus 로고
    • Vascular effects of biologic agents in RA and spondyloarthropathies
    • Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 2009;5(12):677-84
    • (2009) Nat Rev Rheumatol , vol.5 , Issue.12 , pp. 677-684
    • Szekanecz, Z.1    Kerekes, G.2    Soltész, P.3
  • 89
    • 84874089328 scopus 로고    scopus 로고
    • Effects of TNF-A inhibitors upon the mechanisms of action of VEGF
    • Murdaca G, Spanò F, Miglino M, Puppo F. Effects of TNF-a inhibitors upon the mechanisms of action of VEGF. Immunotherapy 2013;5(2):113-15
    • (2013) Immunotherapy , vol.5 , Issue.2 , pp. 113-115
    • Murdaca, G.1    Spanò, F.2    Miglino, M.3    Puppo, F.4
  • 90
    • 41349096428 scopus 로고    scopus 로고
    • Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension
    • Bargagli E, Galeazzi M, Bellisai F, et al. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 2008;75:346-9
    • (2008) Respiration , vol.75 , pp. 346-349
    • Bargagli, E.1    Galeazzi, M.2    Bellisai, F.3
  • 91
    • 84871720484 scopus 로고    scopus 로고
    • Monocrotaline-induced pulmonary arterial hypertension is attenuated by tnf-alpha antagonists via the suppression of tnf-alpha expression and nf-kappab pathway in rats
    • Wang Q, Zuo XR, Wang YY, et al. Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-alpha antagonists via the suppression of TNF-alpha expression and NF-kappaB pathway in rats. Vascul Pharmacol 2013;58(1-2):71-7
    • (2013) Vascul Pharmacol , vol.58 , Issue.1-2 , pp. 71-77
    • Wang, Q.1    Zuo, X.R.2    Wang, Y.Y.3
  • 92
    • 19644364586 scopus 로고    scopus 로고
    • The benefit/risk profile of TNFblocking agents: Findings of a consensus panel
    • Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNFblocking agents: Findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36
    • (2005) Semin Arthritis Rheum , vol.34 , pp. 819-836
    • Hochberg, M.C.1    Lebwohl, M.G.2    Plevy, S.E.3
  • 93
    • 79957927386 scopus 로고    scopus 로고
    • Anti-TNF therapy: Safety aspects of taking the risk
    • Rosenblum H, Amital H. Anti-TNF therapy: Safety aspects of taking the risk. Autoimmun Rev 2011;10:563-8
    • (2011) Autoimmun Rev , Issue.10 , pp. 563-568
    • Rosenblum, H.1    Amital, H.2
  • 94
    • 33846144397 scopus 로고    scopus 로고
    • Immunogenicity, efficacy and adverse events of adalimumab in RA patients
    • Bender NK, Heilig CE, Dr€oll B, et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007;27:269-74
    • (2007) Rheumatol Int , vol.27 , pp. 269-274
    • Bender, N.K.1    Heilig, C.E.2    Droll, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.